Feed forward artificial neural network: Tool for early detection of ovarian cancer

Scientia Pharmaceutica

Volumn 79, Issue 3, 2011, Pages 493-505

  Thakur, Ankita ^a,b   Mishra, Vijay ^b   Jain, Sunil K ^b  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b ADINA Institute of Pharmaceutical Sciences   (India)

Author keywords

Neural networks; Ovarian cancer; SELDI; Serum proteomics

Indexed keywords

ALGORITHM; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; FEED FORWARD ARTIFICIAL NEURAL NETWORK; GENETICS; HUMAN; MEDICAL RESEARCH; OVARY CANCER; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

EID: 80051742112     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1105-11     Document Type: Article

References (24)

1. Jayde V, White K, Blomfield P. Symptoms and diagnostic delay in ovarian cancer: a summary of the literature. Contemp Nurse. 2009; 34: 55-65. PMid:20230172
2. Das PM, Bast Jr RC. Early detection of ovarian cancer. Biomark Med. 2008; 2: 291-303. doi:10.2217/17520363.2.3.291
3. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs. 2008; 68: 771-789. doi:10.2165/00003495-200868060-00004
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300. doi:10.3322/caac.20073
5. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001; 22: 255-288. doi:10.1210/er.22.2.255
6. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006; 95: S161-S192. doi:10.1016/S0020-7292(06)60033-7
7. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983; 309: 883-887. doi:10.1056/NEJM198310133091503
8. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst. 2001; 93: 1458-1464. doi:10.1093/jnci/93.19.1458
9. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002; 287: 1671-1679. doi:10.1001/jama.287.13.1671
10. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999; 238: 375-385. doi:10.1016/S0378-1119(99)00342-X
11. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572-577. doi:10.1016/S0140-6736(02)07746-2
12. Kozak KR. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005; 17: 4589-4596. doi:10.1002/pmic.200500093
13. Yu JK, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B. 2005; 6: 227-231. doi:10.1631/jzus.2005.B0227
14. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. Serum protein finger printing coupled with a pattern matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002; 62: 609-614. PMid:12097261
15. Qu Y. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminated prostate cancer from nonprostate patients. Clin Chem. 2002; 48: 1835-1843. PMid:12324514
16. Ball G, Mian S, Holding F, Allibone RO, Lowe J, Ali S, Li G, McCardle S, Ellis IO, Creaser C, Rees RC. An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumors and rapid identification of potencial biomarkers. Bioinformatics. 2002; 18: 395-404. doi:10.1093/bioinformatics/18.3.395
17. Lilien RH, Farid H, Donald BR. Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum. J Comput Biol. 2003; 10: 925-946. doi:10.1089/106652703322756159
18. Sorace JM, Zhan M. A data review and reassessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics. 2003; 4: 24. doi:10.1186/1471-2105-4-24
19. Wu B, Abbott T, Fishman D, McMurray W, Mor G, Stone K, Ward D, Williams K, Zhao H. Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data. Bioinformatics. 2003; 19: 1636-1643. doi:10.1093/bioinformatics/btg210
20. FDA-NCI Clinical Proteomics Program Databank website. http://home.ccr.cancer.gov/ncifdaproteomics/ppatterns.asp.
21. Schalkoff R. Artificial Neural networks. Mcgraw Hill, Publishers, 1997: 146-118.
22. Duda RO, Hart PE. Pattern Classification and Scene Analysis. Wiley Interscience Publication, New York. 1973: 24-30.
23. Bishop CM. Neural Networks for Pattern Recognition. Oxford University Press, New York, 1995.
24. Maglaveras N, Stamkopoulos T, Diamantaras K, Pappas C, Strintzis M. ECG pattern zecognition and classification using non-linear transformations and neural networks, A review. Int J Med Inform. 1998; 52: 191-208. doi:10.1016/S1386-5056(98)00138-5